Tessera Therapeutics Announces FDA Clearance of IND Application for its Lead In Vivo Gene Editing Program TSRA-196 for AATD

Tessera Therapeutics, the biotechnology company pioneering a new approach in genetic medicine known as Gene Writing™, today announced that the U.S. Food and Drug Administration (FDA) has cleared its ...
Seeking Alpha

FibroBiologics Files IND Application with the U.S. FDA to Advance Clinical Development of CYPS317 in Patients with Psoriasis

HOUSTON, Dec. 31, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development ...
Seeking Alpha

IMUNON Files IND Application to Begin Human Testing of IMNN-101

The application follows guidance provided to IMUNON (IMNN) in Pre-IND meeting with the FDA LAWRENCEVILLE, N.J., March 13, 2024 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage ...
The Manila Times

Levicept Announces FDA Acceptance of IND Application for LEVI-04, a Potentially Disease-Modifying Treatment for Osteoarthritis

Levicept Ltd, a biotechnology company focused on the development of LEVI-04, a first-in-class treatment for osteoarthritis (OA), today announces the US Food and Drug Administration (FDA) has accepted ...
Hosted on MSN

Immuron submitts IND application to FDA for clinical development of IMM-529

Immuron (IMRN) announced that it has submitted an Investigational New Drug, or IND, application to the FDA for clinical development of IMM-529. Under this new IND, Immuron is proposing the development ...
Nasdaq

Silo Pharma, Inc. Plans IND Application Submission for PTSD Drug SPC-15 with Potential Phase 1 Trial in 2026

Silo Pharma, Inc. announced plans to submit an investigational new drug (IND) application for SPC-15, a novel intranasal treatment for Post-Traumatic Stress Disorder (PTSD), by the end of 2025, ...